{"id":49775,"date":"2022-10-18T23:01:59","date_gmt":"2022-10-18T21:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/"},"modified":"2022-10-18T23:01:59","modified_gmt":"2022-10-18T21:01:59","slug":"exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/","title":{"rendered":"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022"},"content":{"rendered":"
\n

\n\u2013 Conference Call and Webcast to Follow at 5:00 p.m. ET \/ 2:00 p.m. PT \u2013<\/i>\n<\/p>\n

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc.<\/a> (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close. At 5:00 p.m. ET \/ 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company\u2019s website.\n<\/p>\n

<\/a><\/p>\n

\nTo access the webcast link, log onto www.exelixis.com<\/a> and proceed to the News & Events \/ Event Calendar page under the Investors & Media heading. Please connect to the company\u2019s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 888-338-9509 (domestic) or 412-902-4281 (international) and ask to be joined into the Exelixis conference call to participate by phone.\n<\/p>\n

\nA telephone replay will be available until 8:00 p.m. ET on November 3, 2022. Access numbers for the telephone replay are: 877-344-7529 (domestic) and 412-317-0088 (international); the passcode is 6992264. A webcast replay will also be archived on www.exelixis.com<\/a> for one year.\n<\/p>\n

\nAbout Exelixis<\/b>\n<\/p>\n

\nFounded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX\u00ae<\/sup> (cabozantinib), COMETRIQ\u00ae<\/sup> (cabozantinib), COTELLIC\u00ae<\/sup> (cobimetinib) and MINNEBRO\u00ae<\/sup> (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery \u2014 all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor\u2019s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com<\/a>, follow @ExelixisInc<\/a> on Twitter or like Exelixis, Inc.<\/a> on Facebook.\n<\/p>\n

\nExelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.<\/i>\n<\/p>\n

\nCOTELLIC is a registered trademark of Genentech, Inc.<\/i>\n<\/p>\n

\nMINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors Contact:<\/b>
Susan Hubbard<\/i>
Executive Vice President, <\/i>Public Affairs & Investor Relations<\/i>
Exelixis, Inc.<\/i>
650-837-8194<\/i>
shubbard@exelixis.com<\/i><\/a>\n<\/p>\n

\nMedia Contact:<\/b>
Hal Mackins<\/i>
For Exelixis, Inc.<\/i>
415-994-0040<\/i>
hal@torchcommunications.com<\/i><\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Conference Call and Webcast to Follow at 5:00 p.m. ET \/ 2:00 p.m. PT \u2013 ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close. At 5:00 p.m. ET \/ 2:00 p.m. PT, Exelixis management will host … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49775","6":"format-standard","7":"category-industry"},"yoast_head":"\nExelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Conference Call and Webcast to Follow at 5:00 p.m. ET \/ 2:00 p.m. PT \u2013 ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close. At 5:00 p.m. ET \/ 2:00 p.m. PT, Exelixis management will host ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-18T21:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221018006164\/en\/610803\/21\/exelixis_id_rgb_2c.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022\",\"datePublished\":\"2022-10-18T21:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/\"},\"wordCount\":482,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018006164\\\/en\\\/610803\\\/21\\\/exelixis_id_rgb_2c.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/\",\"name\":\"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018006164\\\/en\\\/610803\\\/21\\\/exelixis_id_rgb_2c.jpg\",\"datePublished\":\"2022-10-18T21:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018006164\\\/en\\\/610803\\\/21\\\/exelixis_id_rgb_2c.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018006164\\\/en\\\/610803\\\/21\\\/exelixis_id_rgb_2c.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/","og_locale":"en_US","og_type":"article","og_title":"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022 - Pharma Trend","og_description":"\u2013 Conference Call and Webcast to Follow at 5:00 p.m. ET \/ 2:00 p.m. PT \u2013 ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close. At 5:00 p.m. ET \/ 2:00 p.m. PT, Exelixis management will host ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-18T21:01:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221018006164\/en\/610803\/21\/exelixis_id_rgb_2c.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022","datePublished":"2022-10-18T21:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/"},"wordCount":482,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018006164\/en\/610803\/21\/exelixis_id_rgb_2c.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/","url":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/","name":"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018006164\/en\/610803\/21\/exelixis_id_rgb_2c.jpg","datePublished":"2022-10-18T21:01:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221018006164\/en\/610803\/21\/exelixis_id_rgb_2c.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221018006164\/en\/610803\/21\/exelixis_id_rgb_2c.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exelixis-to-release-third-quarter-2022-financial-results-on-tuesday-november-1-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49775"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49775\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}